Last reviewed · How we verify

Jiangsu Hengrui Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Jiangsu Hengrui Pharmaceutical Co., Ltd. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Butorphanol and Propofol Butorphanol and Propofol marketed
Fentanyl and Propofol Fentanyl and Propofol marketed Opioid agonist + sedative-hypnotic combination Mu opioid receptor (fentanyl); GABA-A receptor (propofol) Anesthesiology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Jiangsu Hengrui Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Jiangsu Hengrui Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jiangsu-hengrui-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related